Incyte CEO Hervé Hoppenot has been telling anyone who'll listen that his biotech is undervalued and underestimated, and now, with promising late-stage results for its lead drug in a rare blood cancer, the company has a shot at blockbuster sales alongside partner Novartis.
Hot on the heels of detailing promising pivotal data on ruxolitinib, Incyte ($INCY) filed for FDA approval of the myelofibrosis drug. On Saturday investigators for Incyte and Novartis reported that
With a solid set of favorable late-stage data from two Phase III trials in its hands, Novartis ($NVS) has mapped out a relatively short path to blockbuster status for the experimental cancer drug
An experimental JAK inhibitor under development at Novartis and Incyte hit its primary endpoint in a second late-stage trial, putting the program on track to a second quarter NDA and a possible